-- Funding to support clinical development of multiple antibody-drug conjugate (ADC) programs -- Utilizing the Synaffix platform designed to minimize off-target toxicity and improve efficacy -- ...
It doesn’t matter how well a drug kills cancer cells if the patient doesn’t stay on treatment. Side effects lead many patients to interrupt dosing of a drug regimen, allowing cancer to advance, said ...
KIVU-107 is the first PTK7-targeting ADC with a DAR4 exatecan payload, engineered for exceptional stability and highly selective on-tumor delivery. Preclinical data demonstrate deeper and durable anti ...
SAN FRANCISCO--(BUSINESS WIRE)--Kivu Bioscience, a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class therapeutics, announced today the close of a $92 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback